MediPharm Labs Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

[email protected] (Simply Wall St)
1 min read

In This Article:

MediPharm Labs (TSE:LABS) Full Year 2023 Results

Key Financial Results

  • Revenue: CA$33.1m (up 50% from FY 2022).

  • Net loss: CA$13.1m (loss narrowed by 56% from FY 2022).

  • CA$0.04 loss per share (improved from CA$0.11 loss in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

MediPharm Labs Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 14%.

The company's shares are up 38% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for MediPharm Labs (1 is a bit concerning!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Recommended Stories